Ruxolitinib is indicated for the treatment of intermediate- or high-risk myelofibrosis in adults, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
Ruxolitinib is indicated for the treatment of polycythemia vera in adults with an inadequate response to or intolerance of hydroxyurea.
Ruxolitinib is indicated for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients aged 12 years and older.
Ruxolitinib is indicated for the treatment of chronic graft-versus-host disease in adult and pediatric patients aged 12 years and older after failure of one or two lines of systemic therapy.
Indicated for the treatment of intermediate- or high-risk myelofibrosis in adult···【more】
Release date:2026-10-21Recommended:2